Norwegian pharmaceutical company Ultimovacs ASA (Oslo:ULTI) announced on Monday a Phase II DOVACC collaboration study in ovarian cancer with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN).

The randomised Phase II clinical trial will evaluate Ultimovacs' proprietary universal cancer vaccine, UV1, in combination with AstraZeneca's durvalumab, a PD-L1 checkpoint inhibitor, and its PARP inhibitor, olaparib, in patients with relapsed ovarian cancer.

More than 30 hospitals in around 10 European countries will participate in the trial. Topline data on the primary endpoint is expected in 2023.

Ultimovacs will provide its UV1 vaccine and AstraZeneca will provide the PD-L1 and PARP inhibitors for the study. Innovation Norway has granted Ultimovacs NOK10m (approximately EUR1m) to support the execution of the trial.